Business Context and Reporting Period
This Form 8-K is filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on March 30, 2023. The filing serves to announce the Company's financial results for the year and quarter ended December 31, 2022, as detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover report and does not contain specific numerical data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 8-K. The document solely directs readers to the attached press release for operational results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer under General Instruction B.2 of Form 8-K. It states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liability of that section. No specific guidance, outlook, or risk factors are detailed in this excerpt.
Investor Verification Checklist
- Verify the correct registrant name is Ocuphire Pharma, Inc. (Ticker: OCUP), as the input metadata incorrectly listed "Opus Genetics, Inc."
- Review Exhibit 99.1 (the Press Release dated March 30, 2023) to obtain actual financial figures for the year and quarter ended December 31, 2022.
- Confirm the Company's status as an Emerging Growth Company (indicated by a checkmark in the filing).
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.